Trial Information
Summary: Treatment-Resistant Depression Registry
Depression is a mood disorder that can have profound personal,
social, and financial implications. Depression is recurrent for
most patients and chronic for many others. Vagus Nerve Stimulation
(VNS) Therapy is FDA approved for the treatment of chronic or
recurrent depression for patients who have not had an adequate
response to four or more standard antidepressant treatments.
Patients that have been offered VNS therapy qualify to
participate in this observational registry. The registry will
collect information about subjects with treatment-resistant
depression, including response to treatments, quality of life, and
use of healthcare services. Those subjects who plan to be treated
with VNS Therapy will provide the date of surgical evaluation
and/or surgical implantation and will be followed for 5 years from
that date. Subjects who decide not to go through with the procedure
will be randomly assigned to be followed for either 2 or 5 years as
controls. An initial evaluation will be preformed using
questionnaires concerning the subject's medical and psychiatric
history. Once enrolled in the study, subjects will be tracked for
2-5 years. Follow up visits or phone calls will require subjects to
answer questions concerning health, depression, and treatment for
depression 4 times for the first year and 2 times a year for the
next 1-4 years.
Subjects will be paid $50 for each completed registry visit and
telephone call for a total of $700 for completion of the entire
study. It is important to note that Cedars-Sinai does not provide
VNS therapy nor does it provide funding to subjects wishing to
receive this treatment.
Patient Inclusion Criteria:
- Subject experiencing current major depressive episode
- Subject has been in their current depressive episode for two
years or longer, or has had at least three lifetime episodes
including current episode
- Subject has had inadequate response to four or more adequate
antidepressant treatments
- Subject is 18 years of age or older
Patient Exclusion Criteria:
- Subject has history of schizophrenia, schizoaffective disorder,
and other psychotic disorder, or a current major depressive episode
that includes psychotic features
- Subject currently enrolled in a double-blind investigational
study
- Subject has already received VNS Therapy
- Subject has history of rapid cycling bipolar disorder
|
Contact:
Lindsay Crist, Study Coordinator
Cedars-Sinai Medical Center
8730 Alden Dr. Room E123
Los Angeles, CA 90048
Telephone: 310-423-6515
Fax: 310-423-0888
Email:
|
|

If you would like to learn more about participating in this study, please send an e-mail message using the form below.
Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.
This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.
Trial listings updated: June 1, 2008 at 6:33:09 AM